New combo therapy tested for patients too sick for standard chemo
NCT ID NCT05245682
Summary
This early-phase study is testing the safety and side effects of combining a new oral drug called tolinapant with standard radiation therapy. It is for patients with locally advanced head and neck cancer who have not had prior treatment and cannot receive the usual chemotherapy drug, cisplatin. The goal is to see if this combination is safe and tolerable, and if it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.